Table 3.
Univariate analysis
| Prognostic factor | Definition | Avg. N | HR (95% CI) | Pairwise P-value | Overall P-value |
|---|---|---|---|---|---|
| AdV AAUC0-16 | Continuous | 241 | 1.99 (1.69–2.35) | <0.0001 | |
| Peak AdV viremia0-16 | Continuous | 241 | 1.47 (1.29–1.67) | <0.0001 | |
| Days < 1000 copies/ml0-16 | Continuous | 241 | 0.96 (0.95–0.97) | <0.0001 | |
| Days with undetectable viremia0-16w | Continuous | 241 | 0.96 (0.95–0.97) | <0.0001 | |
| 2-week change in AdV viremia | Continuous | 241 | 1.35 (1.15–1.59) | 0.0003 | |
| Change in AdV viremia over time | Continuous | 241 | 1.54 (1.39–1.71) | <0.0001 | |
| Lymphocyte counts (t) | ≥900 | 65.0 | <0.0001 | ||
| 300–899 | 76.0 | 1.91 (0.48–7.56) | 0.3557 | ||
| <300 | 77.3 | 10.95 (3.18–37.71) | 0.0001 | ||
| CDV (t) use | No | 121 | 1.00 | 0.0310 | |
| Yes | 120 | 1.98 (1.06–3.68) | |||
| Maximum GvHD stage | 0 | 174 | 1.00 | 0.0153 | |
| 1, 2 | 39 | 0.76 (0.29–1.97) | 0.5738 | ||
| 3, 4 | 28 | 2.67 (1.30–5.51) | 0.0076 | ||
| Renal replacement (t) | No | 229 | 1.00 | <0.0001 | |
| Yes | 12 | 28.41 (13.02–61.98) | |||
| Gender | Male | 159 | 1.00 | 0.1170 | |
| Female | 82 | 1.62 (0.89–2.95) | |||
| Type of donor | MRD or MUD | 124 | 1.00 | 0.0221 | |
| MMD/Hapl/CBU | 117 | 2.08 (1.11–3.89) | |||
| Comorbiditiesa | None | 147 | 1.00 | 0.0132 | |
| ≥1 | 94 | 2.14 (1.17–3.91) | |||
| AdV disease | No | 158 | 1.00 | <0.0001 | |
| Yes | 83 | 2.94 (1.60–5.39) |
CBU cord blood (units), CDV cidofovir, Hapl haploidentical, HR hazard ratio, MMD mismatched donor, MRD matched related donor, MUD matched unrelated donor
aListed in Supplementary Table 1